1. Home
  2. SBSI vs OMER Comparison

SBSI vs OMER Comparison

Compare SBSI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southside Bancshares Inc.

SBSI

Southside Bancshares Inc.

HOLD

Current Price

$33.45

Market Cap

936.3M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$14.80

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBSI
OMER
Founded
1960
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
936.3M
772.8M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
SBSI
OMER
Price
$33.45
$14.80
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$35.33
$32.50
AVG Volume (30 Days)
73.2K
1.1M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
4.42%
N/A
EPS Growth
N/A
98.15
EPS
0.78
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$28.87
N/A
Revenue Next Year
$5.82
$233.22
P/E Ratio
$42.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.32
$2.95
52 Week High
$34.53
$17.65

Technical Indicators

Market Signals
Indicator
SBSI
OMER
Relative Strength Index (RSI) 55.91 68.99
Support Level $31.79 $10.82
Resistance Level $33.68 $17.65
Average True Range (ATR) 0.93 0.66
MACD -0.02 0.09
Stochastic Oscillator 58.94 81.88

Price Performance

Historical Comparison
SBSI
OMER

About SBSI Southside Bancshares Inc.

Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: